Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ImmunityBio, Inc.
M.D. Anderson Cancer Center
Deciphera Pharmaceuticals, LLC
NKGen Biotech, Inc.
National Institutes of Health Clinical Center (CC)
RedHill Biopharma Limited
Barbara Ann Karmanos Cancer Institute
Hadassah Medical Organization
Fox Chase Cancer Center